Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 216 people enrolled
- Started
- 7 Nov 2019
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Treatment strategy trial
- Record updated
- 8 June 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- ICU stay >48 hours or admission in a tertiary care hospital prior to the current admission
- Two or more risk factors for IFI from amongst the following:-; Mechanically ventilated at least ≥ 48 hours; Treatment with broad-spectrum antibacterial agents for more than 3 days; Arterial or central vein catheter ≥ 2days; Diabetes Mellitus; Total parenteral nutrition ≥ 48 hours; Acute renal failure requiring any form of renal replacement therapy ≥48hours; Pancreatitis related hospitalization > 7days in last 3 months; Steroid use, immunosuppressant use in the preceding 30 days; High disease score as defined as MELD≥20 or APACHE II ≥16; Refractory ascites, norfloxacin prophylaxis; Gastrointestinal tract surgery, abdominal perforation or anastomotic leaks or any invasive procedures or surgeries in the last 7days; Chronic pulmonary diseases including COPD or Tuberculosis; Moderate to severe sarcopenia as defined by The Royal Free Hospital-global assessment (RFH-GA) scale60 (As per Appendix "4" ); Firm diagnosis of H1N1 influenza infection in the last 3 months
- Clinical suspicion of IFI as defined by any of the following:; Evidence of unresolved sepsis/SIRS(≥ 2/4) despite appropriate broad-spectrum antibiotics beyond 3days; Recrudescence of fever after a period of defervescence of at least 48 hours while still on antibiotics and without other apparent cause; Tracheobronchial ulcer, nodule, plaque or pseudo-membrane; Sino-nasal infection: features of acute sinusitis with at least 1 of acute localized pain, nasal ulcer, eschar, orbital involvement or; Respiratory symptoms:; Worsening respiratory insufficiency despite appropriate ventilator support and antibiotics; Any 2 of Pleuritic chest pain, pleural rub, dyspnea, hemoptysis; Characteristic skin lesions suspected of fungal infection; Unexplained worsening of encephalopathy after initial improvement
Who cannot take part
- Human immunodeficiency virus seropositivity on rapid card test/ELISA, or currently on combination antiretroviral therapy (cART)
- Hepatocellular carcinoma or other active malignancy
- Known hypersensitivity or contraindication to Liposomal AmB or any other AmB preparation
- Moribund patients as defined as; ≥ 4 organ failure as per CLIF-SOFA score; Signs of brainstem death- absent brainstem reflexes; Expected ICU stay <48 hours
- Neutrophil count of less than 500/mm3
- Current or recent antifungal treatment in the past 1 months
- Pregnancy as confirmed by urine pregnancy test or lactation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Early treatment of invasive fungal infections (IFI) may prevent undue mortality in acute on chronic liver failure (ACLF) patients. We aim to study the impact of early empiric treatment (based on clinical suspicion) of IFI as compared to pre-emptive treatment (based on biomarkers and culture positivity) on the outcomes in ACLF patients with suspected IFI in a randomized trial. The ACLF patients with clinically suspected IFI would be randomly allocated to empiric treatment or pre-emptive treatment group and followed up clinically to assess the impact on survival, clinical outcomes and cost-effectiveness and safety of such an approach. The protocol is designed to cut- down unnecessary usage and to curtail the duration of antifungals use in ICUs based on biomarkers/culture-driven stoppage rules. The results will fuel further studies on formal cost-effective analysis and antimicrobial stewardship protocols in ACLF patients.
The 2 groups in the trial
- Early Empiric groupOther group
Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
Treatment: Treatment strategy trial
- Pre-emptive groupExisting treatment, for comparison
Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
Treatment: Treatment strategy trial
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Empirical Versus Pre-emptive Systemic Anti-fungal Therapy in Acute-on-Chronic Liver Failure Patients With Suspected Invasive Fungal Infections: a Randomized Controlled Trial
- Publications
- Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial.The American journal of gastroenterology, 2026
- Record updated
- 8 June 2025